Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy

Zhou, Lixin; Li, Tao; Huang, Yiran; Sha, Jianjun; Sun, Peng; Liu, Dong

doi:10.1038/aja.2009.81

Cited by 23 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 In fact, increased expression of MMP2 in cancer cells has been shown as a predictor of decreased prostate cancer disease-free survival. [17][18][19][20] MMPs are currently being evaluated for their 21 These patients underwent radical prostatectomy and did not receive any preoperative treatment. The histopathologic features of tumor specimens were reviewed by the Department of Pathology and classified according to the World Health Organization (WHO) criteria (NCCN Updates Prostate Cancer Guidelines in National Comprehensive Cancer Network, http:// www.nccn.org).…”

Section: Resultsmentioning

confidence: 99%

SUMO-specific protease 1 promotes prostate cancer progression and metastasis

et al. 2012

View full text Add to dashboard Cite

SUMO-specific protease 1 (SENP1) is a member of de-SUMOylation protease family and has an important role in the regulation of androgen receptor-dependent transcription and hypoxia signaling. This activity profile of SENP1 prompted us to investigate whether SENP1 is involved in the pathogenesis of prostate cancer. In previous studies, we have detected the overexpression of SENP1 in both precancerous prostate intraepithelial neoplasia (PIN) lesions and prostate cancer tissue samples from patients. Whereas our whole-animal model has demonstrated that SENP1 induction is critical for prostate cell transformation, the role of SENP1 in prostate cancer progression is still unknown. In this study, we show that SENP1 expression directly correlates with prostate cancer aggressiveness and reccurrence, by analyzing more than 150 prostate cancer specimens. Modulating SENP1 level dictates colony formation of prostate cancer cell lines, tumor growth in nude mice and also prostate cancer cell migration and invasion. Silencing SENP1 level in highly metastatic prostate cancer cells perturbs their ability to metastasize to the bone and initiates secondary tumors. Mechanistically, the expression of two critical bone remodeling proteins, matrix metalloproteinase 2 (MMP2) and MMP9, is regulated by SENP1 through the HIF1α signaling pathway. All these results show the contribution of SENP1 to the progression of prostate cancer, and suggest that SENP1 may be a prognostic marker and a therapeutic target for metastasis in prostate cancer patients.

show abstract

Section: Resultsmentioning

confidence: 99%

SUMO-specific protease 1 promotes prostate cancer progression and metastasis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Multiple mechanisms that alter the charge of histones and that are associated with increased chromatin opening and rate of transcription are well characterized. IHC analysis of global levels of mono-, di-and trimethylated H3K4 (H3K4me1/2/3), which are marks of active transcription, and acetylated H3K18 (H3K18ac), which marks TSS in actively transcribed genes or genes poised for transcription, have been shown to be independent predictors of recurrence in PC patients (Seligson et al 2005, Ellinger et al 2010, Zhou et al 2010.…”

Section: Introductionmentioning

confidence: 99%

Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer

Braadland

Urbanucci

2019

Endocrine-Related Cancer

View full text Add to dashboard Cite

Tumor evolution is based on the ability to constantly mutate and activate different pathways under the selective pressure of targeted therapies. Epigenetic alterations including those of the chromatin structure are associated with tumor initiation, progression and drug resistance. Many cancers, including prostate cancer, present enlarged nuclei, and chromatin appears altered and irregular. These phenotypic changes are likely to result from epigenetic dysregulation. High-throughput sequencing applied to bulk samples and now to single cells has made it possible to study these processes in unprecedented detail. It is therefore timely to review the impact of chromatin relaxation and increased DNA accessibility on prostate cancer growth and drug resistance, and their effects on gene expression. In particular, we focus on the contribution of chromatinassociated proteins such as the bromodomain-containing proteins to chromatin relaxation. We discuss the consequence of this for androgen receptor transcriptional activity and briefly summarize wider gain-of-function effects on other oncogenic transcription factors and implications for more effective prostate cancer treatment.

show abstract

“…Previously, we showed that the H3 trimethylation status at lysine 4 can predict the risk of BCR in low-grade PCa (Gleason score ≤ 6) after RP [ 17 ]. Therefore, UHRF1 might play an important role in tumourigenesis in the prostate.…”

Section: Introductionmentioning

confidence: 99%

UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy

Yang

Chen

et al. 2016

J Exp Clin Cancer Res

Self Cite

View full text Add to dashboard Cite

BackgroundBiochemical recurrence (BCR) is widely used to define the treatment success and to make decisions on if or how to initiate a secondary therapy, but uniform criteria to define BCR after radical prostatectomy (RP) is not yet completely assessed. UHRF1 has a unique function in regulating the epigenome by linking DNA methylation with histone marks. The clinical value of UHRF1 in PCa has not been well done. Therefore, we evaluated the prognostic significance of UHRF1.MethodUHRF1 expression in PCa cells was monitored by qRT-PCR and Western blot analyses. UHRF1 expression was knocked down using specific siRNAs, and the effects of knockdown on the proliferation, migration, cell cycle, and apoptosis of PCa cell lines were investigated. UHRF1 protein expression was evaluated in 225 PCa specimens using immunohistochemistry in tissue microarrays. Correlations between UHRF1 expression and the clinical features of PCa were assessed.ResultsThe results showed that UHRF1 was overexpressed in almost all of the PCa cell lines. In PCa cells, UHRF1 knockdown inhibited cell proliferation and migration, and induced apoptosis. UHRF1 expression levels were correlated with some clinical features of PCa. Multivariate analysis showed that UHRF1 expression was an independent prognostic factor for biochemical recurrence-free survival.ConclusionsUHRF1 functions as an oncogene in prostate cancer and appears to be capable of predicting the risk of biochemical recurrence in PCa patients after radical prostatectomy, and may serve as a potential therapeutic target for PCa.

show abstract

Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy

Cited by 23 publications

References 39 publications

SUMO-specific protease 1 promotes prostate cancer progression and metastasis

SUMO-specific protease 1 promotes prostate cancer progression and metastasis

Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer

UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy

Contact Info

Product

Resources

About